The American Parkinson’s Disease Association is supporting researchers with $2.35 million in new funding

From genetic mutations to augmented reality, APDA-funded researchers delve into cutting-edge Parkinson’s research in search of answers.

New YorkAnd the 08 September 2022 /PRNewswire-PRWeb/ – file American Parkinson’s Disease Association (APDA) has just been awarded $2.35 million To support cutting-edge Parkinson’s disease (PD) research for the 2022-2023 funding year — more than 25 percent more than the previous year. The Funded research projects It will explore a range of important and innovative topics including: understanding the molecular underpinnings of anxiety in PD, investigating the role of DNA damage in genetic mutations in PD, testing augmented reality in freezing walking therapy, and more. The APDA is focused on investing in the most promising clinicians and scientific projects focused on discovering the cause(s) and finding cure(s) for Parkinson’s disease (PD) and has been a co-funding partner in many of the major scientific achievements in PD since the organization began.

With someone diagnosed with Parkinson’s disease every nine minutes, this research is critical as we push for better treatments and ultimately a cure. APDA is consistent in its research focus – identifying and supporting researchers early in their careers to encourage them to either begin or continue to dedicate themselves to PD research, as well as assisting established researchers in pursuing new and innovative ideas. Leslie A ChambersAPDA President and CEO comments, “Part of APDA’s motto is ‘Hope for Progress’ and it is very rewarding to support our researchers as they develop their theories and obtain important empirical data and initial proof of concept. Often this raw data allows them to apply for and obtain larger grants from National Institutes of Health and other funding institutions”. Chambers continues, “Without the initial support from APDA, some research projects may not start at all. We are proud to help make this progress and provide hope for everyone affected by PD.”

Grants are awarded for the next year in the form of four postdoctoral fellowships, thirteen research fellowships, one diversity grant in Parkinson’s disease research, eight APDA Centers for Advanced Research, and one George C Kotzias Memorial Fellowship, APDA’s Prestigious Award.

For the third year in a row, the APDA is awarding a Specialized Scholarship to a scholar who focuses on diverse and underrepresented communities. The APDA created the first of its kind in Parkinson’s Disease Research Grant in 2019 to encourage and support researchers committed to diversity-focused research so that we can learn more about how the disease affects different populations and better serve people with Parkinson’s. from all societies.

All APDA Scholarships are awarded through a competitive application process and reviewed by APDA Scientific Advisory Board (SAB) Composed of scholars with a wide range of backgrounds and expertise in all areas relevant to PD research. The SAB meets annually to review all grant proposals and set the scientific direction for APDA’s annual research investment. “As always, it’s a very difficult decision-making process, and SAB has to make very difficult choices” Rebecca GilbertMD, PhD, and chief scientific officer, APDA. “Thanks to the generosity of our donors, we were thrilled to be able to fund more research this year, enabling us to say yes to some truly innovative projects and promising researchers.” (Get to know some of the researchers in this video.)

APDA Research Scholarships 2022-2023

The George C. Cotzias Fellowship is a prestigious APDA scholarship awarded to a young physician and scientist of exceptional promise who is establishing a career in research, education, and clinical services relevant to Parkinson’s disease. The award is for three years and is designed to fund a long-term project focused on professional development. This year’s winner is:

  • My neighbor isMasters, Ph.DBrigham women’s hospital, Boston Massachusetts (Utilizing protein palmitoylation to correct vesicle trafficking defects in Parkinson’s disease)

The APDA Diversity in Parkinson’s Disease Research Scholarships are one-year grants that examine health inequality and/or differences between unstudied PD communities, across the spectrum of race, origin, geography, socioeconomic conditions, and gender. This year’s winner is:

  • Erin FosterPh.DUniversity of WashingtonAnd the St. Louis, Missouri (Understanding engagement in research, clinical care, and community services among people of color with Parkinson’s disease)

Postdoctoral fellowships are awarded to support postdoctoral scholars who have recently completed their doctoral work and whose research promises to provide new insights into the pathophysiology, etiology, and treatment of Parkinson’s disease. This year’s award winners are:

  • Tyler campPh.DUniversity of Illinois Urbana-ChampaignAnd the Champaign, Illinois (alphaHypo-synuclein and membrane localization in Parkinson’s disease)

  • Stefan GrimaldiPh.DMassachusetts Public Hospital, Boston, Massachusetts (Longitudinal changes in brainstem-based biomarkers of prodromal Parkinson’s disease with ultra-high-field MRI)

  • Anastasia Kozkina, Ph.D.Brigham women’s hospital, Boston, Massachusetts (Development of human IPSC models to examine host-strain interactions in cellulopathy)

  • Andrew ZimnikPh.DColumbia UniversityAnd the New York, New York (The role of basal ganglia output in the acquisition and implementation of complex motor skills)

Research grants are awarded to investigators who conduct innovative research in the field of professional development at major academic institutions around the world. United State. This year’s award winners are:

  • Eamonn DixonPh.DUniversity of California, Davis. Davis, California (alpha-Synuclein-dependent remodeling of membrane contact sites as a driver of Parkinson’s disease neurotoxicity.)

  • Ronald EmsonPh.DVanderbilt UniversityAnd the Nashville, Tennessee (LRRK2-mediated ADAR therapies in Parkinson’s disease)

  • Sunil KumarPh.DUniversity of DenverAnd the Denver, Colorado (Therapeutic validation of new targets associated with Parkinson’s disease)

  • Japsang Lee, Ph.D.Johns Hopkins University School of MedicineAnd the Baltimore, MD (In vitro and in vitro efficacy of the induced compound selected from the OASIS drug screening platform)

  • James LiaoPh.D – Cleveland Clinic, Cleveland, Ohio (External visual cues versus internal AR visual cues for frozen gait therapy)

  • Michael LudatoPh.DUniversity of Massachusetts Chan Medical College, Worcester, Massachusetts (Single-cell whole genome sequence analysis of DNA damage and somatic mutation in the human Parkinson’s disease brain)

  • Ryan RomichPh.D – Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD (An automated mobile health approach to video-based motor assessment in Parkinson’s disease)

  • Hiroaki SekiaMasters, Ph.D Mayo Clinic Jacksonville. Jacksonville, Florida (Differential gene and protein expression by digital spatial profiling in neurons with synuclein oligomers or Lewy bodies)

  • Martin TetroPh.D – University Hospital Center Montreal, Montreal, Quebec, Canada (Aberrant immune regulation in Parkinson’s disease by Stearoyl-CoA Desaturase)

  • Nicholas TreitchPh.DNew york university medical school, New York, New York (Revealing how linear circuits gradually change as dopamine neurons deteriorate)

  • Hisashi OmimoriMasters, Ph.D Boston Children’s Hospital, Boston, Massachusetts (Specific Dopamine Synapse Regulator for Childbirth and Parkinson’s Disease)

  • Laura Volpicelli DalyPh.DThe University of Alabama at BirminghamAnd the Birmingham, AL (Activation of mGluR4 to rescue amygdala defects caused by alpha-synuclein)

  • Scott WaldmanMasters, Ph.DThomas Jefferson UniversityAnd the Philadelphia, Pennsylvania (targeting GUCY2C for neuroprotection in experimental Parkinson’s disease)

In addition, ongoing funding has been granted to eight APDA Centers for Advanced Research To support various programs including research interns, clinical fellowship programs, early stage discovery programs and later stage clinical translation. These centers facilitate research that is at the forefront of investigating the causes, treatments, and eventual treatment of Parkinson’s. The current APDA Centers for Advanced Research are:

  • Boston University School of MedicineAnd the Boston, Massachusetts

  • Emory University School of MedicineAnd the Atlanta, GA

  • Mayo Clinic, Jacksonville, Florida

  • Rutgers Robert Wood Johnson College of Medicine, New Brunswick, New Jersey

  • The Brigham women’s hospital, Boston, Massachusetts

  • The University of Alabama at Birmingham medical school, Birmingham, AL

  • University of Pittsburgh medical Center, Pittsburgh, Pennsylvania

  • University of Washington medical school, St. Louis, Missouri

“The work being done as a result of grants in this new funding cycle will have an incredible impact on the world of PD,” Chambers says. “This work is only possible due to the consistent support of APDA’s generous donors.”
Learn more about these recipients and the exciting work they do and browse all APDA-funded research by visiting http://www.apdaparkinson.org/research/what-we-fund/.

Researchers and clinicians interested in applying for APDA funding can visit http://www.apdaparkinson.org/research For details on funding opportunities 2023-2024. Letters of Intent can be submitted for the scholarship cycle 2023-2024 starting from September 28, 2022 With a deadline of December 2, 2022.

Those who wish to support APDA’s critical research with a donation can do so by visiting http://www.apdaparkinson.org and clicking the Donate button or mailing a check payable to APDA to: APDA, PO Box 61420, Staten Island, New York 10306.

The American Parkinson’s Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to help more than one million people in United State With PD living life to the fullest in the face of this chronic neurological disorder. Founded in 1961, APDA has collected and invested more than $226 million To provide outstanding services and educational programs to patients, raise public awareness of the disease, and support research designed to unravel the mysteries of PD and ultimately put an end to the disease. To join us in the fight against Parkinson’s disease and learn more about the support the APDA provides nationwide through our network of chapters, Information and Referral (I&R) centers, as well as the National Research Program and Advanced Research Centers, please visit us at http://www.apdaparkinson.org.

# # #

Media connection

Eloise CaggianoAmerican Parkinson Disease Association (APDA), 718-737-8151, ecaggiano@apdaparkinson.org

SOURCE American Parkinson Disease Association (APDA)

Leave a Comment